Skip to main content
. 2020 Aug 26;10(9):1674. doi: 10.3390/nano10091674

Figure 2.

Figure 2

Potential molecular pathways involved in the Tmab-mediated inhibition of tumor progression once this antibody binds to the domain IV of HER2, blocking its homo- and hetero-dimerization. Such pathways are: (a) the inhibition of the MAPK and PI3K signaling cascades; (b) ADCC; (c) the blockage of the angiogenesis process.